Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor

US8207160B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Wilfried Braje · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Wilfried Lubisch · Mannheim, DE
• Roland Grandel · Dossenheim, DE
• Karla Drescher · Ludwigshafen, DE
• Hervé Geneste · Schifferstadt, DE
• Liliane Unger · Ludwigshafen, DE
• Daryl Sauer · Pleasant Prairie, US

Key dates

• Filing date: Dec 17, 2004
• Grant date: Jun 26, 2012
• Expiry date: Nov 22, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to tetrahydrobenzazepines of the general formula Iin which the variables Ar, A, B, Y, R1 and R2 have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides.The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.